Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA.

Sci Rep · 2021 · PMC7794355 · PMID 33420287

Europe PMC DOI

hedged sentence

0.1220

closest p · 2.4× alpha

0.1220

boldest claim

The sentences

did not reach statistical significanceP = 0.122not close (p > 0.1)

The cumulative incidence of grade II-IV aGVHD in the MSD-PTCy cohort was lower than that in the control cohort, 7.7% (95% CI 0.4–30.3) vs 30.0% (95% CI 11.8–50.7), but the difference did not reach statistical significance ( P = 0.122) (Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.